Drug Trial Radar · NCT06724900
A Study Assessing KB304 for the Treatment of Wrinkles in Women
Last checked: Nov 19, 2026Latest source record: May 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
19
Actual
Start
Nov 20, 2024
Primary completion
Jul 2025
Study completion Aug 2025
Sponsor
- Lead sponsor
- Krystal Biotech, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of this study is to investigate the safety and efficacy of KB304, an investigational gene therapy to correct moderate to severe wrinkles in the décolleté region (V-shaped chest area). KB304 is an investigational gene therapy that delivers functional, full-length human collagen (COL3) and elastin (tropoelastin) to the skin through small injections using the Sponsor's genetically engineered Herpes Simplex Virus (HSV-1) vector. The study is a randomized double-blind study and participants will receive either KB304 (active group) or placebo (inactive group).
Conditions
- Wrinkles in Decolletage
- Pigmentation
- Décolleté Wrinkles
Interventions
KB304Biological
Genetically modified herpes simplex type 1 virus
0.9% Normal Saline (NS)Drug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of KB304 versus placebo administered by intradermal injectionTime frame: Up to 4 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Steve Yoelin Medical Associates
Newport Beach, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.